Lenalidomide: all 818 studies that test it

Page 4 of 9. Open to participants first (111), then studies with results posted, then the rest; newest registration first within each.

• Lenalidomide, Thalidomide and Dexamethasone in Treating Participants With Relapsed or Refractory Multiple MyelomaCompletedNCT00966693Phase 1/2Results posted
• Study of Lenalidomide to Evaluate Safety and Efficacy in Patients With Relapsed or Refractory Chronic Lymphocytic LeukemiaCompletedNCT00963105Phase 2Results posted
• A Phase 2 Trial of Bevacizumab, Lenalidomide, Docetaxel, and Prednisone (ART-P) for Treatment of Metastatic Castrate-Resistant Prostate CancerCompletedNCT00942578Phase 2Results posted
• Lenalidomide and GM-CSF in Treating Patients With Prostate CancerCompletedNCT00939510Phase 1/2Results posted
• A Safety Confirmation Study on Lenalidomide With Dexamethasone In Japanese Patients With Previously Treated Multiple MyelomaCompletedNCT00928486Phase 3Results posted
• Study Of The Effectiveness & Safety Of Lenalidomide Versus Chlorambucil As First Line Therapy For Elderly Patients With B-Cell CLL (The ORIGIN Trial)CompletedNCT00910910Phase 3Results posted
• A Pharmacokinetic And Pharmacodynamic Study Of Oral Lenalidomide (Revlimid) In Subjects With Low- Or Intermediate-1-Risk Myelodysplastic SyndromesCompletedNCT00910858Phase 1/2Results posted
• Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VDCompletedNCT00908232Phase 2Results posted
• Lenalidomide and Doxorubicin Hydrochloride Liposome in Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal CancerTerminatedNCT00903630Phase 1/2Results posted
• Nonmyeloablative Stem Cell Transplantation for Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00899431Phase 2Results posted
• Phase 1-2 of Azacitidine + Lenalidomide for Previously Untreated Elderly Patients With Acute Myeloid Leukemia (AML)CompletedNCT00890929Phase 1/2Results posted
• A Pilot Study of Lenalidomide, Melphalan and Dexamethasone in AL AmyloidosisCompletedNCT00890552Not applicableResults posted
• A Study to Determine the Efficacy of Lenalidomide Versus Investigator's Choice in Patients With Relapsed or Refractory Mantle Cell Lymphoma (MCL)CompletedNCT00875667Phase 2Results posted
• Trial of High Dose Lenalidomide in Patients With MDS and AML With Trilineage DysplasiaTerminatedNCT00867308Phase 2Results posted
• Lenalidomide Following Fludarabine/Rituximab (FR) in Untreated Chronic Lymphocytic Leukemia (CLL)CompletedNCT00860457Phase 2Results posted
• Combination of Revlimid, Melphalan and Dexamethasone as First Line Treatment for Multiple MyelomaTerminatedNCT00843310Phase 2Results posted
• Efficacy and Safety of Lenalidomide in Combination With Cyclosporine A in Patients With Myelodysplastic SyndromesTerminatedNCT00840827Phase 2Results posted
• Lenalidomide With Gemcitabine in Treatment of Untreated Advanced Carcinoma of the PancreasCompletedNCT00837031Phase 2Results posted
• Idarubicin + Cytarabine and Lenalidomide in Patients With Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML)CompletedNCT00831766Phase 1/2Results posted
• Study of CC-5013 to Evaluate Safety, Pharmacokinetics and Effectiveness for Japanese Patients With Symptomatic Anemia Associated With Myelodysplastic Syndrome With a Del(5)(q31-33) Abnormality.CompletedNCT00812968Phase 2Results posted
• Lenalidomide (Revlimid®) Plus Low-dose Dexamethasone (Ld x 4 Cycles) Then Stem Cell Collection Followed by Randomization to Continued Ld or Stem Cell Transplantation (SCT) Plus Maintenance LCompletedNCT00807599Phase 2Results posted
• Trial on Lenalidomide Given as Maintenance Therapy for Relapsed Diffuse Large B Cell LymphomaCompletedNCT00799513Phase 2Results posted
• A Pilot Study to Investigate the Effect of Cytotoxic Therapy and/or Radiotherapy on Cancer Related Sleep Disturbances in CLL and Breast Cancer Patients Experiencing FatigueCompletedNCT00792077Phase 2Results posted
• Lenalidomide and Low-Dose Dexamethasone in Patients With Previously Treated Multiple Myeloma and Kidney DysfunctionTerminatedNCT00790842Phase 1/2Results posted
• Lenalidomide, Rituximab, Cyclophosphamide, and Dexamethasone in Treating Patients With Previously Untreated Low-Grade Non-Hodgkin LymphomaCompletedNCT00784927Phase 2Results posted
• Combination Therapy Using Lenalidomide (Revlimid)- Low Dose Dexamethasone and Rituximab for Treatment of Rituximab-Resistant, Non-Aggressive B-Cell LymphomasCompletedNCT00783367Phase 2Results posted
• A Study to Evaluate the Efficacy and Safety of Lenalidomide as Maintenance Therapy for Patients With B-Cell Chronic Lymphocytic Leukemia (CLL) Following Second Line TherapyCompletedNCT00774345Phase 3Results posted
• Lenalidomide With or Without Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00772915Phase 2Results posted
• Lenalidomide and Rituximab as Treatment of Chronic Lymphocytic LeukemiaCompletedNCT00759603Phase 2Results posted
• Study of Lenalidomide in Previously Untreated, Symptomatic Chronic Lymphocytic Leukemia (CLL)TerminatedNCT00751296Phase 2Results posted
• A Phase 1b/2, Dose-Escalation Study of Elotuzumab (Humanized Anti-CS1 Monoclonal IgG1 Antibody) in Relapsed Multiple MyelomaCompletedNCT00742560Phase 2Results posted
• A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" TrialCompletedNCT00737529Phase 2Results posted
• Lenalidomide, Fludarabine & Cyclophosphamide in Advanced Chronic Lymphocytic Leukemia Not Responding to TherapyCompletedNCT00727415Phase 1/2Results posted
• Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple MyelomaCompletedNCT00724568Phase 1/2Results posted
• Lenalidomide for Advanced Hepatocellular Cancer:A Phase II TrialCompletedNCT00717756Phase 2Results posted
• A Dose Range Finding Study of Lenalidomide in Non-5q Chromosome Deletion in Low and Intermediate Risk Myelodysplastic Syndrome (MDS) PatientsTerminatedNCT00699842Phase 1/2Results posted
• Lenalidomide in Combination With Rituximab in Treating Participants With Stage III/IV Indolent Non-Hodgkin LymphomaCompletedNCT00695786Phase 2Results posted
• Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance TherapyCompletedNCT00691704Phase 2Results posted
• Study to Determine Efficacy and Safety of Lenalidomide Plus Low-dose Dexamethasone Versus Melphalan, Prednisone, Thalidomide in Patients With Previously Untreated Multiple MyelomaCompletedNCT00689936Phase 3Results posted
• Sorafenib, Lenalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple MyelomaTerminatedNCT00687674Phase 1Results posted
• Lenalidomide (Revlimid) for the Treatment of Refractory Cancer PainTerminatedNCT00684242Phase 2Results posted
• Melphalan, Lenalidomide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00679367Phase 2Results posted
• Lenalidomide (Revlimid®) as Second Line Therapy in Patients With Chronic Graft-Vs-Host Disease (GVHD)TerminatedNCT00675441Phase 2Results posted
• Lenalidomide, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Stage II, Stage III, or Stage IV Diffuse Large Cell or Follicular B-Cell LymphomaCompletedNCT00670358Phase 1/2Results posted
• Study of Lenalidomide as a Treatment for Neuropathy Associated With Monoclonal Gammopathy of Undetermined SignificanceTerminatedNCT00665652Phase 2Results posted
• A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's LymphomaTerminatedNCT00655668Phase 2Results posted
• Study Evaluating Toxicity & Efficacy of Lenalidomide(Revlimid®)in Chemotherapy-Naïve AIPC PatientsCompletedNCT00654186Phase 2Results posted
• Vorinostat (MK-0683, SAHA [Suberoylanilide Hydroxamic Acid]) + Lenalidomide + Dexamethasone in Multiple Myeloma (MM) (MK-0683-074)CompletedNCT00642954Phase 1Results posted
• Evaluation of Lenalidomide (REVLIMID®) to Treat Subjects With Cutaneous Lupus Erythematosus (CLE)CompletedNCT00633945Not applicableResults posted
• Rituximab, Lenalidomide, and Bortezomib in Mantle Cell LymphomaCompletedNCT00633594Phase 1/2Results posted
• Lenalidomide in Chronic Lymphocytic Leukemia (CLL) Patients With Residual DiseaseCompletedNCT00632359Phase 2Results posted
• A Companion Study for Studies THAL-MM-003, CC-5013-MM-009, and CC-5013-MM-010 for Subjects With Multiple MyelomaCompletedNCT00622336Phase 3Results posted
• Lenalidomide in Treating Patients With Progressive or Recurrent Multiple Myeloma After a Donor Stem Cell TransplantCompletedNCT00619684Phase 2Results posted
• Pegylated Liposomal Doxorubicin, Low Freq Dexamethasone & Revlimid (Dd-R) in Newly Diagnosed Multiple Myeloma (MM)CompletedNCT00617591Phase 2Results posted
• Lenalidomide in Comb w/Rituximab for Pts w/CD5+/CD20+ Hem Malignancies Who Relapse/Progress After RituximabCompletedNCT00609869Phase 2Results posted
• Phase 1b Multicenter Study of Carfilzomib With Lenalidomide and Dexamethasone in Relapsed Multiple MyelomaCompletedNCT00603447Phase 1Results posted
• Rituximab, Pentostatin, Cyclophosphamide, and Lenalidomide in Treating Patients With Previously Untreated B-Cell Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaCompletedNCT00602836Phase 2Results posted
• Melphalan, Prednisone, and Thalidomide or Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00602641Phase 3Results posted
• Fludarabine and Rituximab With or Without Lenalidomide or Cyclophosphamide in Treating Patients With Symptomatic Chronic Lymphocytic LeukemiaCompletedNCT00602459Phase 2Results posted
• Lenalidomide and Rituximab in Treating Patients With Recurrent and/or Refractory Multiple MyelomaTerminatedNCT00567229Phase 2Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic AmyloidosisCompletedNCT00564889Phase 2Results posted
• Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell LymphomaCompletedNCT00553644Phase 2Results posted
• Lenalidomide in Older Patients With Acute Myeloid Leukemia Without Chromosome 5q AbnormalitiesCompletedNCT00546897Phase 2Results posted
• Phase II Study of Revlimid®, Oral Cyclophosphamide and Prednisone for Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00540644Phase 2Results posted
• Lenalidomide in Relapsed or Refractory Classical Hodgkin LymphomaCompletedNCT00540007Phase 2Results posted
• Phase II Study of Dexamethasone, Thalidomide and Lenalidomide for Subjects With Relapsed or Refractory Multiple MyelomaTerminatedNCT00538824Phase 2Results posted
• Phase II Study of Thalidomide, Clarithromycin, Lenalidomide, and Dexamethasone for Newly Diagnosed Multiple MyelomaCompletedNCT00538733Phase 2Results posted
• Fludarabine, Rituximab, and Lenalidomide in Minimally Treated/Untreated Patients With Chronic Lymphocytic Leukemia (CLL)CompletedNCT00536341Phase 1/2Results posted
• Lenalidomide as Initial Treatment of Patients With Chronic Lymphocytic Leukemia (CLL) Age 65 and OlderCompletedNCT00535873Phase 2Results posted
• Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With DexamethasoneTerminatedNCT00522392Phase 3Results posted
• Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma PatientsCompletedNCT00507442Phase 1/2Results posted
• Lenalidomide, Sunitinib, and Cyclophosphamide in Treating Patients With Stage IV Eye MelanomaTerminatedNCT00482911Phase 2Results posted
• A Multicenter, Single-Arm, Open-Label Expanded Access Program for Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00478777Phase 3Results posted
• Lenalidomide, Cyclophosphamide, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00478218Phase 2Results posted
• Melphalan, Prednisone, and Lenalidomide in Treating Patients With Newly Diagnosed Multiple MyelomaCompletedNCT00477750Phase 1/2Results posted
• A Study to Evaluate Lenalidomide Combined With Dexamethasone in Relapsed or Refractory Diffuse Large B-Cell LymphomaTerminatedNCT00474188Phase 2Results posted
• Lenalidomide in Treating Patients With Relapsed Mycosis Fungoides/Sezary SyndromeCompletedNCT00466921Phase 2Results posted
• Treating Patients With Prostate Cancer That Did Not Respond to Hormone TherapyCompletedNCT00460031Phase 2Results posted
• Lenalidomide, Dexamethasone, and Clarithromycin in Treating Patients Who Have Undergone Stem Cell Transplant for Multiple MyelomaCompletedNCT00445692Phase 2Results posted
• Lenalidomide and Vaccine Therapy in Treating Patients With Relapsed or Refractory Multiple MyelomaCompletedNCT00445484Phase 2Results posted
• Lenalidomide in Previously Treated Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic LymphomaCompletedNCT00439231Phase 2Results posted
• A Study of CC-5013 Plus Dexamethasone Versus Dexamethasone Alone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00424047Phase 3Results posted
• A Multicentre, Single-arm, Open-label Safety Study of Lenalidomide Plus Dexamethasone in Previously Treated Subjects With Multiple MyelomaCompletedNCT00420849Phase 3Results posted
• A Study of Revlimid in the Treatment of Non-Hodgkin's LymphomaCompletedNCT00413036Phase 2Results posted
• Bevacizumab, Lenalidomide, and Dexamethasone in Patients With Relapsed or Refractory Stage II or III Multiple MyelomaCompletedNCT00410605Phase 2Results posted
• A Study to Compare MPR With MP in Newly Diagnosed Multiple Myeloma Subjects 65 Years Old or Older.CompletedNCT00405756Phase 3Results posted
• Lenalidomide in Treating Patients With Advanced or Unresectable Kidney CancerCompletedNCT00403169Phase 2Results posted
• Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple MyelomaCompletedNCT00378209Phase 2Results posted
• Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple MyelomaActive, not recruitingNCT00378105Phase 1/2Results posted
• Revlimid in Patients With Acute Myelogenous Leukemia and Myelodysplastic SyndromeCompletedNCT00360672Phase 2Results posted
• Lenalidomide for Patients With Myelofibrosis (MF)CompletedNCT00352794Phase 2Results posted
• Lenalidomide in Treating Older Patients With Acute Myeloid LeukemiaCompletedNCT00352365Phase 2Results posted
• Lenalidomide and Azacitidine in Treating Patients With Advanced Myelodysplastic SyndromesCompletedNCT00352001Phase 1/2Results posted
• Study of 2 Different Doses of Revlimid in Biochemically Relapse Prostate CancerCompletedNCT00348595Phase 1/2Results posted
• Lenalidomide and Rituximab in the Treatment of Relapsed Mantle Cell Lymphoma (MCL) and Diffuse Large B-Cell LymphomaCompletedNCT00294632Phase 1/2Results posted
• REVLIMID® (Lenalidomide) for Therapy of Radioiodine-Unresponsive Papillary and Follicular Thyroid CarcinomasCompletedNCT00287287Phase 2Results posted
• Lenalidomide (Revlimid) in Chronic Lymphocytic Leukemia (CLL)CompletedNCT00267059Phase 2Results posted
• Rituximab and/or Lenalidomide in Treating Patients With Follicular Non-Hodgkin's Lymphoma That is Not Refractory to RituximabCompletedNCT00238238Phase 2Results posted
• Lenalidomide and Prednisone in Treating Patients With MyelofibrosisCompletedNCT00227591Phase 2Results posted
• Lenalidomide (Revlimid®, CC-5013) in Subjects With Relapsed or Refractory Indolent Non-Hodgkin's LymphomaCompletedNCT00179673Phase 2Results posted

← Lenalidomide overview